Poster zum Thema "Clinical Proteomics"

Zurück
  • P-I-0275
Proteomics multiplex technologies: an ideal clinical tool for biomarker discovery and precision medicine for CNS conditions
  • Houari Abdesselem (Doha / QA)
  • P-I-0276
Investigating molecular mechanisms and novel biomarkers of postoperative recurrence in hepatocellular carcinoma: proteomic analysis of FFPE samples
  • P-I-0277
Identifying mass spectrometry-based biomarkers for predicting tumor recurrence in lung cancer
  • P-I-0278
Quantitative proteome analysis of normal and degenerated intervertebral disc tissue
  • P-I-0279
Comprehensive proteomic and glycoproteomic profiling of Organoids derived from human hepatocellular carcinoma
  • P-I-0280
Exploring the role of TMOD2 in colorectal cancer development and progression through functional proteomics
  • P-I-0281
High-throughput LC-MS for plasma proteomics in patients with stroke
  • P-I-0282
Impact of the tumor microenvironment in splenic metastasis in high-grade serous ovarian cancer revealed by quantitative proteomics
  • P-I-0283
Saliva and stool proteomic profiling revealed potential biomarkers for inflammatory bowel diseases and colorectal carcinoma
  • P-I-0284
Phosphoproteomics and depletion studies in human serum – revealing the differences between healthy state, obesity and type 2 diabetes mellitus
  • P-I-0285
Proteome signatures in urinary extracellular vesicles enable prostate cancer detection
  • P-I-0286
Comprehensive in vivo multiomics analysis of Alzheimer's disease pathogenesis in plasma
  • P-I-0287
Enrichment strategies for fast and sensitive analysis of cerebrospinal fluid
  • P-I-0288
Machine learning identifies clinical sepsis phenotypes that translate to the plasma proteome level
  • P-I-0289
High sensitivity analysis of tau phospho, non-phospho, and MTBR peptides in Alzheimer's disease CSF and plasma using Orbitrap Astral
  • P-I-0290
Targeted proteomics of synapse-associated pathological processes in neurodegenerative diseaeses
  • P-I-0291
Characterizing inflammatory cytokines in plasma, tracheal aspirate, and urine samples of children hospitalized with tracheostomy-associated respiratory infections utilizing Olink technology
  • P-I-0292
Plasma proteomic biomarkers of respiratory failure severity and mechanical ventilation duration among critically ill children
  • P-I-0293
Development and evaluation of a novel biomarker-based risk stratification platform for obesity-related complications using targeted proteomics
  • P-I-0294
A carrier-based quantitative proteomics method applied to biomarker discovery in pericardial fluid
  • P-I-0295
Towards skin cohort proteomics studies: A fine-tuned MS-based workflow applied to Pachyonychia congenita
  • P-I-0296
Proteomic profiling uncovers key proteins in ascites extracellular vesicles from Ovarian cancer patients: insight to tumor plasticity and prognosis
  • P-I-0297
Antibodyome analysis of schizophrenia by Escherichia coli proteome microarrays
  • P-I-0298
Reducing inter-observer variability: harnessing molecular insights for clinical applications
  • P-I-0299
The in vivo measure and mathematical modeling of protein turnover in multiple biological compartments and across patient cohorts
  • P-I-0301
Molecular basis of progressive familial intrahepatic cholestasis 3. A proteomics study
  • P-I-0302
A rapid and economical workflow for protein biomarker discovery using agilent 6495D triple quadrupole LC/MS system
  • P-I-0303
Profiling the proteome response to tamoxifen
  • P-I-0304
Single cell and clinical proteomics profiling in non-small cell lung cancer (NSCLC)
  • P-I-0305
Comprehensive proteomics analysis of plasma from ApoE- and LDLR- deficient mice reveals atherosclerosis biomarkers with potential application in clinic
  • P-I-0306
Quantitative tissue analysis reveals AK2, COL1A1, & PLG protein signatures: targeted therapeutics for meningioma
  • P-I-0307
Proteome changes by P2X7 receptor stimulation of microvesicles and exosomes from human glioblastoma stem cells
  • P-I-0308
Proteomic analyses of the urothelial cancer landscape reveal highly distinct prognostic and predictive subtypes
  • P-I-0309
Targeted Proteomics goes clinical as primary endpoint: a case study
  • P-I-0311
Integrating proteomics into diagnostic molecular pathology reports to support molecular tumor board decisions
  • P-I-0313
Proteomic characterisation of clear cell renal cell carcinoma in patients with Von Hippel-Lindau Syndrome
  • P-I-0314
Impact of CFTR modulators on the blood proteome
  • P-I-0315
The proteogenomic subgroups of relapsed Osteosarcoma
  • P-I-0316
Standardized, fully automated scalable plasma workflows enabled by the Evotip pure
  • P-I-0317
The comparison and correlation of in vitro and in vivo UPEC proteomes
  • P-I-0318
Urine proteomic analysis of patients with schizophrenia
  • P-I-0319
Urinary proteome profiling for children with autism using data-independent acquisition proteomics
  • P-I-0320
Abundant serum proteins potentially discriminate normal and GDM pregnancy: from peptidome to intact proteins
  • P-I-0321
DIA, DDA and PRM strategies for biomarker identification and validation in plasma cohorts of COVID-19 patients with varying severity
  • P-I-0322
Multi-omics analysis of tissue and serum samples from patients suffering from Crohn's patients identifies pathological mechanisms
  • P-I-0323
Developmental-specific proteomic vulnerabilities of Leukemia
  • P-I-0324
Proteomic signatures of Mitochondrial and immune responses as predictors of melanoma evolution
  • P-I-0325
CSF proteomic analysis across the Alzheimer's disease continuum
  • P-I-0327
Discovery, verification and validation of urinary protein signatures in HIV-associated nephropathy in South Africa
  • P-I-0328
Mag-Net™ Urine: Improved and complementary workflow for clinical urinary proteomics
  • P-I-0329
Quantitative SRM assay development for oral cancer prognosis in a clinical routine
  • P-I-0330
Mass spectrometric comparison of blood matrices and sample preparation techniques. Benchmarking clinical sample SOPs and different proteolysis methods for plasma and serum by LC-MSMS in DIA mode
  • P-I-0331
In-depth analysis of the plasma proteome: Are we enriching extracellular vesicles, platelets, or soluble proteins?
  • P-I-0332
Unraveling the molecular mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Leveraging Proteomics and PTMs analysis for the development of precision medicine
  • P-I-0333
Proteomic Characterization of Papillary Thyroid Carcinoma with Distant Metastasis
  • P-I-0334
Sample preparation comparison for the investigation of unstable peptidomic biomarkers of hypertension in human plasma
  • P-I-0335
Proteomic landscaping of high-grade serous ovarian carcinoma identifies stearoyl-CoA desaturase 5 as a potential predictive biomarker for poly(ADP-ribose) polymerase inhibitor response
  • P-I-0336
Transmembrane protein 160 (TMEM160) is involved in cell proliferation and migration in lung and cervical cancer
  • P-I-0337
Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory
  • P-I-0339
Uncovering H. Pylori associated and independent Gastric cancer signature by tissue phosphoproteomic analysis
  • P-I-0340
Multi-proteomics identifies knee osteoarthritis progression markers in hoffa's fat pad
  • P-I-0341
Effect of a western diet and age on liver proteome in male and female rats
  • P-I-0342
Proteomic strategy to mitigate off-target liabilities for targeted protein degraders
  • P-I-0343
Integrating urine and plasma proteomics to uncover age-specific molecular signatures of pediatric diseases
  • P-I-0344
Novel serum biomarkers in intrahepatic cholangio-carcinoma: a pilot proteomic exploration
  • P-I-0345
Proteomic profiling of left ventricular hypertrophy regression in severe aortic valve stenosis after valve replacement
  • P-I-0346
Acrivon Predictive Precision Proteomics (AP3)-guided development and prospective clinical Phase 2 validation of the response-predictive OncoSignature test for the CHK1/2 inhibitor, ACR-368
  • P-I-0347
Advancing clinical diagnostics and prognostics through proteomics: insights from core facility perspective
  • P-I-0348
Proteomic and proteogenomic characterization of triple negative breast cancer
  • P-I-0349
Optimization of SAX-Based enrichment of plasma extracellular vesicles for high-throughput deep phenotyping of the heart failure syndrome
  • P-I-0350
Urinary proteomic analysis reveals new molecular subtypes of lupus nephritis
  • P-I-0351
Multi-tiered proteome analysis displays the hyper-permeability of the rheumatoid synovial compartment for plasma proteins
  • P-I-0352
The tape-stripping procedure for the identification of protein N-termini within skin specimens
  • P-I-0353
Salivary chemical barrier proteins in oral squamous cell carcinoma – alterations in the defense mechanism of the oral cavity
  • P-I-0354
Exosomal protein biomarkers for early prediction for dengue severity in pediatric population using quantitative proteomics approach
  • P-I-0355
Benchmarking sample preparation and data analysis for clinical proteomics of human biofluids
  • P-I-0356
Providing an analytical platform for state-of-the-art absolute apolipoprotein quantification in human blood plasma using prm-PASEF
  • P-I-0357
Streamlined extraction of proteins from clinical Trizol samples via aggregate capture on magnetic beads
  • P-I-0358
Identification of novel prognostic protein biomarkers from maternal serum of women with recurrent pregnancy loss
  • P-I-0359
Profiling the blood proteome in autoimmune disease using proximity extension assay
  • P-I-0360
Impact of non-aqueous fluid flow on protein profile in glaucoma drainage device implants
  • P-I-0361
Proteomic strategies uncover novel aging and age-related disease signatures in the human post-menopausal ovary
  • P-I-0362
Proteomic profiling of circulating tumor cells for precision oncology
  • P-I-0363
Nanoparticle-based proteomics analysis of human biofluid samples from different patient cohorts
  • P-I-0364
Proteomic alterations in early-stage breast cancer: insights from tumor-adjacent normal tissues analysis
  • P-I-0365
Ubiquitin: characterization of a host cell protein covalently attached to a monoclonal antibody product by LC-MS/MS
  • P-I-0366
Targeted proteomic analysis for monitoring of multiple myeloma progression
  • P-I-0367
Proteomic profiling of preeclampsia
  • P-I-0368
Quantitative assessment of multiple pathogen exposure, autoimmunity and immune dynamics at scale
  • P-I-0369
Predictive biomarker discovery for immune checkpoint inhibitor in metastatic MMRd endometrial cancer through deep proteomic profiling of FFPE tissue samples
  • P-I-0370
Plasma protein biomarker discovery for ovarian cancer
  • P-I-0372
Exploring proteomic signatures of high-grade serous carcinoma of the ovary
  • P-I-0373
Decoding CRC progression: impact of patient individuality on the proteomic phenotype
  • P-I-0374
Proteomics uncovers the underlying mechanism of distant metastasis in follicular thyroid carcinoma
  • P-I-0375
Mitochondrial Proteomic Characterization of Thyroid Oncocytic Tumors: Diagnostic Potential of IDH2 as a Biomarker
  • P-I-0376
Serum proteomic analysis reveals molecular features for stratification of chronic obstructive pulmonary disease
  • P-I-0377
Revolutionizing Proteomics: Advanced nanoESI Ion Source with NanoElectrospray Emitters for Unmatched Sensitivity and Robustness
  • P-I-0378
Revealing protein profiles in Parkinson's disease by mass spectrometric analysis of living brain tissue during deep brain stimulation
  • P-I-0379
Single-shot mass spectrometry-based phosphoproteomic analysis of patient-derived formalin-fixed, parrafin-embedded samples reveal tissue specific fingerprints
  • P-I-0380
Pathophysiological subtypes of mild cognitive impairment due to Alzheimer"s disease identified by CSF proteomics
  • P-I-0381
Addressing inter-individual variability in CSF levels of brain-derived proteins across neurodegenerative diseases
  • P-I-0382
Mining proteomic signature of soft tissue sarcoma by mass-spectrometry to find new candidate drug targets
  • P-I-0383
Investigation of inter- and intra-day variability of tear fluid in terms of flow rate, protein concentration and protein composition
  • P-II-0618
Proteomic characterization of Meningioma tissue and serum
  • P-II-0619
Quantitative proteomics identifies proteins and pathways involved in the progression from precancerous gastric lesions in a population of high-cancer gastric risk
  • P-II-0620
Assessment of Hemoglobin-related clinical markers using volumetric absorptive microsampling and data-independent acquisition mass spectrometry
  • P-II-0621
Harmonization of quantitative proteomics data collected across the international cancer proteogenome consortium
  • P-II-0622
Integrative proteomic and AI-based histopathologic profiling reveals new prognostic subclusters in early-stage non-small cell lung cancer
  • P-II-0623
Understanding the proteome changes arising throughout 5-Fluorouracil chemoresistance development in colorectal cancer cells, with special focus on the methyl proteome
  • P-II-0624
ACR-2316: a potent, selective WEE1/PKMYT1 inhibitor rationally designed for superior single agent activity using Acrivon Predictive Precision Proteomics (AP3) for biological SAR
  • P-II-0625
Targeted quantitative proteomics of anticoagulated patients
  • P-II-0626
Proteomic mapping of spatiotemporal dynamics in metastatic colorectal cancer
  • P-II-0628
The promise of the Orbitrap ASTRAL mass-spectrometer for proteomics analysis
  • P-II-0629
Circulating plasma and salivary extracellular vesicles proteomes indicate prognostic signature in oral cancer
  • P-II-0630
The forgotten success story of clinical proteomics: how autoantibodies discovered via proteomics tools are now key diagnostic biomarkers in neurology
  • P-II-0631
Optimizing capivasertib response prediction in cancer: unveiling resistance mechanisms through precision proteomics
  • P-II-0632
Quantification of Her2 expression in Her2-low tumors by targeted mass spectrometry
  • P-II-0633
Serum proteomics of mother-infant dyads carrying HLA-conferred type 1 diabetes risk
  • P-II-0634
Proteomic signatures of the eutopic endometrium of patients with deep bowel endometriosis
  • P-II-0635
Evaluation of new sample preparation methods associated with DIA analysis on Exploris 480 and Tims Tof SCP mass spectrometers to increase proteomic depth on plasma
  • P-II-0636
Why is the peripartum heart a substrate for dilated cardiomyopathy? A data driven investigation of molecular and cellular remodelling.
  • P-II-0637
Peptidomic analysis of cerebrospinal fluid samples reveals new biomarker candidates for amyotrophic lateral sclerosis
  • P-II-0638
Differentially expressed protein biomarkers in early and advanced stage of young triple-negative breast cancer patients
  • P-II-0639
Plasma proteome profiling revealed altered levels of complements in the plasma of interverterbal disc degeneration patients
  • P-II-0640
Plasma proteome profiling revealed altered levels of complements in the plasma of interverterbal disc degeneration patients
  • P-II-0641
Comparative proteomic analysis of breast cancer and normal tissues with deep plasma profiling using the Mag-Net™ workflow
  • P-II-0642
Protein-profiling of liquid biopsies for the differential diagnosis of pancreatic diseases
  • P-II-0643
Cell lines recapitulate the kinase activity profiles of colorectal tumor tissue and predict drug response
  • P-II-0644
A proteomic skin disease atlas for accurate and rapid AI-driven clinical decision making
  • P-II-0645
A translational, high-throughput proteomics platform for the deep analysis of plasma samples
  • P-II-0646
ZenoSWATH proteomics and clustering analysis reveal different modulation patterns in fibroblasts from cystinosis patients by cysteamine
  • P-II-0647
Pharmaco-proteogenomics for synovial sarcoma towards novel therapy
  • P-II-0648
The European cancer moonshot "Biobank" – the heart of cancer studies
  • P-II-0649
Predicting abdominal aortic aneurysms by combining mass spectrometry-based proteomics with clinical data
  • P-II-0650
Proteome analysis with combined DIA and Glyco‑DIA approach of laser microdissected precursor lesions from pancreatobiliary cancer to improve early cancer diagnostics
  • P-II-0651
Clinical proteomics elucidated the complex molecular mechanisms in the progression of dry eye syndrome with different severity levels: a step forward to personalized diagnosis
  • P-II-0652
Development of a plasma proteomics methodology for biomarker discovery of immunocytokine therapy in Glioblastoma
  • P-II-0653
Saliva peptidome as source of possible biomarkers of salivary glands tumor
  • P-II-0654
Time-resolved plasma proteomics predicts survival outcome of COVID-19 patients during hospitalization
  • P-II-0655
Profiling of the pathophysiological mediators of a rare neurodegenerative disease, Friedreich's Ataxia (FRDA)
  • P-II-0656
Requirements and limitations for the preparation of targeted mass spectrometry assays enabling therapeutic drug monitoring
  • P-II-0657
Proteomics signature predictive of early biochemical progression and distant progression after stereotactic body radiotherapy in oligometastatic prostate cancer
  • P-II-0658
Comparative proteomic analysis of human ventricular tissue of over 100 patients undergoing heart transplantation
  • P-II-0659
A high-throughput, in-depth investigation into the immunological effects of Lipopolysaccharide challenged mice in neat plasma on Orbitrap astral mass spectrometer
  • P-II-0660
Quality control for clinical proteomics
  • P-II-0661
An in-depth and high throughput plasma proteomics workflow powered by Orbitrap Exploris 480 mass spectrometer using multi nanoparticle-based workflow
  • P-II-0662
Deep plasma proteomics profiling of healthy humans at two different stages of adulthood
  • P-II-0663
Quantification of intra-amniotic inflammation in late preterm prelabor rupture of membranes associated with the response of amniotic fluid proteome
  • P-II-0664
Biomarker discovery through in-depth characterisation of the serum protein composition of infant victims of silent Abusive Head Trauma (AHT)
  • P-II-0665
Search for novel diagnostic markers of pancreatic ductal adenocarcinoma using secretome and glycoproteom analysis
  • P-II-0666
Vasodilator-stimulated phosphoprotein acts as a potential plasma-derived exosomal protein marker for early detection of colorectal cancer
  • P-II-0667
Sample storage as pre-analytical factor on serum proteome quality
  • P-II-0668
Profiling of the global proteome and the repertoire of N-termini of vitreous humor uncovers alterations of cell adhesiveness and extracellular matrix composition in rhegmatogenous retinal detachment
  • P-II-0669
Endoscope-based cold atmospheric Plasma (PLASMASKOP) as a novel therapeutic tool for the treatment of head and neck cancer
  • P-II-0670
Plasma proteome profiling reveals immunological dynamics in a longitudinal yellow FeverVaccination cohort
  • P-II-0671
Enriching the diagnostic portfolio of the molecular tumor board with proteomics and phosphoproteomics of FFPE samples
  • P-II-0672
Phosphoproteomics adds value to treatment recommendations in molecular tumor boards
  • P-II-0673
Workflow for rapid proteome and phosphoproteome profiling of aging in mouse tissues
  • P-II-0674
Tumour cell-induced platelet aggregation revealed different phenotypes between PDAC plasticity subtypes – A proteomic comparison between two pancreatic cancer cell lines
  • P-II-0675
Exploring extracellular vesicle proteins as source of biomarkers for early detection of meningioma and predicting their therapeutic implications
  • P-II-0676
Search for novel diagnostic markers of chronic kidney disease in cats using proteome analysis
  • P-II-0677
Search for novel diagnostic markers of pancreatic ductal adenocarcinoma using secretome and proteome analysis
  • P-II-0678
Intra-sample three-point quantitative calibration using metabolically labelled QconCATs
  • P-II-0679
Transmembrane glycoprotein GPNMB is a candidate predictive biomarker and potentially a therapeutic target in metastatic renal cell carcinoma
  • P-II-0680
FFPE tissue proteomics (LC-MS/MS): applications in diagnostic molecular pathology
  • P-II-0681
Proteomics-driven biomarker discovery for M3913 in multiple myeloma xenograft models
  • P-II-0682
Proteomic remodeling of the heart following transplantation: the signature of cardiac allograft vasculopathy
  • P-II-0683
Search for novel diagnostic markers of pancreatic ductal adenocarcinoma using secretome analysis
  • P-II-0684
The PATH biobank – fostering breast cancer research
  • P-II-0685
Analysis of women's health-related proteins in dried blood spots
  • P-II-0686
Identifying new immunotherapy targets for pediatric leukemia using cell surface proteome profiling.
  • P-II-0687
Single Cell Deep Visual Proteomics (scDVP) of human hepatocytes in alpha-1 antitrypsin deficiency
  • P-II-0688
MultiOmics landscape of pathotypes in rheumatoid arthritis – enroute to digital health using AI clinical diagnostics by nanoproteomics and AI based imaging diagnostics
  • P-II-0689
An end-to-end (phospho)proteomics data analysis platform for precision oncology of 1000 prospective pan-cancer patients
  • P-II-0690
Insights from proteomic analysis in Crohn's disease
  • P-II-0692
Towards a noninvasive diagnosis of Peri-implantitis: proteomic analysis of Peri-implant crevicular fluid
  • P-II-0693
Comparative proteomic analysis of laser microdissected human glomeruli and tubules in IgA nephropathy
  • P-II-0694
Proteogenomic profiling of mutated proteins in urine extracellular vesicles for non-invasive bladder cancer liquid biopsy
  • P-II-0695
Early detection of liver cancer – the role of extracellular matrix proteins
  • P-II-0696
Efficient Human Plasma Proteome Profiling at up to 240 Samples Per Day
  • P-II-0697
Ultra-deep MS based plasma proteomics in a hand foot and mouth disease cohort
  • P-II-0698
Multiplex mass spectrometry-based analysis of inflammatory proteins and their isoforms in serum samples of analog astronauts
  • P-II-0699
Loss of SDHB manifests differently in the proteomes of neuroendocrine tumors and a tumor-derived cell line model hPheo-1
  • P-II-0700
Urinary proteome profiling of rat and human unveils biomarkers of LRRK2 activity
  • P-II-0701
Proteomic profiling of progressive multiple sclerosis patient brains reveals regional and cell-type protein differences related to disease processes
  • P-II-0702
Dynamic proteomic changes in tumor and immune organs reveal systemic immune response to tumor development
  • P-II-0703
TMT proteomics reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes
  • P-II-0704
Proteomic profiling of IDH-wildtype glioblastoma reveals prognostic subtypes with matching abundances of semi-specific peptides in serum
  • P-II-0705
Monitoring disease status and treatment performance in multiple myeloma
  • P-II-0706
dia-PASEF proteomic analysis of HNSCC tumor and stroma enriched sections from FFPE samples prepared with laser capture microdissection
  • P-II-0707
Morphological and molecular profiling as a pilar of precision medicine: tailoring treatment in late-stage cancer patients
  • P-II-0708
Leveraging the Orbitrap astral mass spectrometer to enable the analysis of low tissue content sample sources
  • P-II-0709
Proteomic characterization of epithelial ovarian cancer delineates molecular signatures and therapeutic targets in distinct histological subtypes
  • P-II-0710
Comparative analysis of EV isolation method for urinary extracellular vesicles proteomics in cancer
  • P-II-0711
Proteomics-guided personalized therapy for advanced primary uterus diffuse large B-cell lymphoma: a case report
  • P-II-0712
Reproducibility and reliability of protein quantity analyzed by DIA quantitative proteomics for urine biomarker discovery
  • P-II-0713
Urine bank in biofluid biomarker center and its usability for biomarker discovery
  • P-II-0714
Discovery and validation of urine biomarkers for kidney nephron/site-specific damages by proteomics and immunoassay
  • P-II-0715
Unlocking biomarker discovery with novel high-throughput LC-MS workflows for translational research on an Orbitrap Astral mass spectrometer
  • P-II-0717
Discrepancies in proteomics data: autopsy versus fresh frozen samples
  • P-II-0718
Proteomics identifies circulating TIMP-1 as a prognostic biomarker for diffuse large B-Cell Lymphoma
  • P-II-0719
Structure-based protein biomarkers for early detection of breast cancer
  • P-II-0720
High-throughput peptidome profiling reveals Ischemic stroke-specific proteolysis changes in plasma
  • P-II-0721
Cross-platform proteomic profiling of plasma extracellular vesicles to identify biomarkers of malignant pulmonary modules
  • P-II-0722
The molecular insights into the glomerulus injury and prognosis of patients with diabetic kidney disease by integrating proteomics and single-sell RNA sequencing
  • P-II-0723
Proteomic and gene panel-based profiling of medullary thyroid cancer for prognosis prediction
    • v1.20.0
    • © Conventus Congressmanagement & Marketing GmbH